Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis

@article{Reis2019BimekizumabTF,
  title={Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis},
  author={J. Reis and R. Vender and T. Torres},
  journal={BioDrugs},
  year={2019},
  pages={1-9}
}
Psoriasis is a chronic inflammatory skin disease with significant psychological and physical impact. Over the last few decades, several highly effective target therapies have been developed, leading to a major paradigm shift in the way psoriatic disease is managed. Despite this, a proportion of patients still do not respond or lose response over time. Bispecific antibodies target two different cytokines simultaneously, potentially offering a better disease control. Interleukin (IL)-17A and IL… Expand
Dual inhibition of IL-17A and IL-17F in psoriatic disease
Psoriasis and psoriatic arthritis are chronic immune-mediated disorders with involvement of interleukin (IL)-17 cytokines in their pathogenesis. IL-17A has been considered to be the most biologicallyExpand
An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
TLDR
The evidence so far for the use in psoriatic arthritis of bimekizumab, the first humanized monoclonal IgG1 antibody that selectively neutralizes both IL-17A and IL- 17F is reviewed. Expand
Bimekizumab: the new drug in the biologics armamentarium for psoriasis
Bimekizumab, a humanized monoclonal IgG1 antibody being currently evaluated for multiple immune-mediated diseases, is mentioned in the recent report by Clarivate, Drugs to Watch in 2021, as one ofExpand
Inhibition of interleukins 17A and 17F in psoriatic arthritis
TLDR
Inhibitors of the IL17 pathway have rewritten treatment paradigms especially for psoriasis control, with up to 50% of patients achieving at least 100% reductions in Psoriasis Area and Severity Index (PASI100) scores. Expand
Preliminary Report on Interleukin-22, GM-CSF, and IL-17F in the Pathogenesis of Acute Anterior Uveitis
TLDR
A novel multi-parametric flow cytometry panel to identify immune dysregulation signatures in HLA B27-associated acute anterior uveitis and axial spondyloarthritis is developed, arguably the first to implicate IL-17F or ILC-3 and MAIT cells in the pathogenesis of AAU. Expand
Role of Interleukin-23/Interleukin-17 Axis in T-Cell Mediated Actions in Hypertension.
TLDR
Current knowledge on the role of these cytokines in immune mechanisms contributing to hypertension are summarized, and the potential of IL-23/IL-17-targeted therapy for treatment of hypertension is discussed. Expand
Role of TH17 Responses in Increasing Herpetic Keratitis in the Eyes of Mice Infected with HSV-1
TLDR
The results suggest that the absence of IL17 protects against HSV-1-induced eye disease, but has no role in protecting against virus replication, latency, or reactivation. Expand
Notch-Hes1 Signaling Regulates IL-17A+γδ+T Cell Expression and IL-17A Secretion of Mouse Psoriasis-Like Skin Inflammation
TLDR
In vitro study demonstrated that DAPT treatment could result in dose-dependent decrease of IL- 17A+γδ+T cell percentage and IL-17A secretion in splenic single cells of model mice. Expand
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis
TLDR
It is concluded that IL-17A promotes migratory and angiogenic activity in tumors, enhances anoikis resistance, and modulates the immune landscape of the tumor microenvironment such changes favor cancer metastasis. Expand
Axial spondyloarthritis: new advances in diagnosis and management
TLDR
The discovery of the interleukin (IL) IL-23/IL-17 pathway revealed key molecules involved in the pathophysiology of axSpA and propelled the generation of antibodies directed toward IL-17A, which are highly effective and demonstrate treatment responses in axSpa that are similar to those observed with anti-TNF agents. Expand
...
1
2
...

References

SHOWING 1-10 OF 54 REFERENCES
AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY
TLDR
Bimekizumab provided rapid and substantial clinical improvements in patients with moderate-to-severe plaque psoriasis, with a safety profile consistent with previous bimekuzumab studies, and nearly all BE aBLE 1 responders completing 60 weeks of bIMEkizumsab treatment maintained complete or almost complete skin clearance. Expand
THU0038 Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells
TLDR
Dual neutralisation ofIL-17A and IL-17F provides evidence for the contribution of IL- 17F to inflammation in joints and skin beyond IL-16A alone and may provide an effective treatment for immune-mediated inflammatory diseases such as PsA. Expand
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
TLDR
IL-17F is supported as a key driver of human chronic tissue inflammation and the rationale for dual neutralisation of IL-17A and IL- 17F in PsA and related conditions is supported. Expand
Anti-IL17 therapies for psoriasis
TLDR
The development and approval of the IL-17 inhibitor agents secukinumab, ixekizuab, and brodalumab has expanded psoriatic treatment with effective options, validating the importance of the pro-inflammatory role of IL- 17 psoriasis pathophysiology. Expand
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
TLDR
The current knowledge around the cytokines belonging to the IL-17 family in relation to skin inflammation in general and psoriasis in particular is summarized, possible clinical implications are discussed, and a comprehensive understanding of the different roles played by theIL-17 cytokines are discussed. Expand
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
TLDR
The primary and key secondary objectives were achieved and a greater percentage of bimekizumab-treated patients achieved ASAS40 (primary endpoint) than placebo (Figure: p<0.001, all doses); no unexpected safety risks were observed; the most frequently reported events were nasopharyngitis and headache. Expand
The role of IL 23 in the treatment of psoriasis
  • L. Puig
  • Medicine
  • Expert review of clinical immunology
  • 2017
TLDR
Specific IL-23p19 blockade with high-affinity monoclonal antibodies seems to be able to induce long-term remissions of the activity in psoriasis and might eventually represent a paradigm change in the treatment of psorosis. Expand
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12‐week randomized, double‐blinded, placebo‐controlled phase 2b trial
TLDR
Dual neutralization of IL‐ 17A and IL‐17F with bimekizumab provided rapid and substantial clinical improvements in patients with psoriasis, with no unexpected or dose‐related safety findings. Expand
Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin
TLDR
Ultrasensitive methods for measuring IL-17A andIL-17F in human serum samples are developed and it is found that serum from psoriasis patients had higher and a broader range of concentrations of both IL- 17 proteins compared to healthy volunteers. Expand
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.
TLDR
This review focuses on the emerging biology of the IL- 17 cytokine family in psoriasis, and on the molecular and genetic information gained from animal models and human clinical studies that confirm IL-17 as a crucial proinflammatory cytokine in psoriatic lesions. Expand
...
1
2
3
4
5
...